Lexicon Pharmaceuticals | LXRX - DEBITO





DEBITO Cambiamento Data
Abbott USD 34.05B 20.19B 2026-03
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 43.37B 867M 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Illumina USD 2.54B 9M 2026-03
Insmed USD 725.8M 1.82M 2026-06
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 54.99B 7.05B 2026-03
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
MacroGenics USD 36.51M 500K 2026-03
MannKind USD 330.96M 36.48M 2026-03
Merck USD 49.12B 222M 2026-03
Moderna USD 1.3B 7M 2026-03
Novartis USD 49.01B 2.02B 2026-06
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Thermo Fisher Scientific USD 43.16B 3.78B 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12